You are here

Pfizer's Anacor deal showcases new wave of eczema therapies

Steroid-free topical ointment and injectable therapy reduce symptoms in late-stage trials without side effects

pfixer180516.jpg
Pfizer Inc's purchase of Anacor Pharmaceuticals Inc heralds an approaching wave of potentially safer and more effective treatments for millions who suffer from eczema, a common skin condition which causes infection-prone rashes that can feel like having poison ivy 24 hours a day.

PFIZER Inc's purchase of Anacor Pharmaceuticals Inc heralds an approaching wave of potentially safer and more effective treatments for millions who suffer from eczema, a common skin condition which causes infection-prone rashes that can feel like having poison ivy 24 hours a day.

More